STAT

MARCH 21, 2024

Prometheus and some other companies have been able to capitalize on creating treatments for conditions like inflammatory bowel disease and psoriasis, while arthritis medications like Humira have brought in billions of dollars in sales. But the field hadn’t quite received the same attention as missions to cure cancer.

Immunization 110

Immunization 110

STAT

OCTOBER 3, 2023

A follow-up study of a first-of-its-kind cancer treatment may reflect systemic biases, the Food and Drug Administration said ahead of an advisory committee meeting Thursday to determine whether the drug should remain on the market. Now, the drug’s manufacturer, Amgen, needs to prove it works.

FDA 96

FDA 96

The Checkup by Singlecare

OCTOBER 16, 2023

If you or a loved one have recently been injured or diagnosed with an illness that impedes your daily life, you might wonder: What medical conditions automatically qualify you for disability? This means you must develop a severe medical ailment on the list of disabling conditions and then meet other criteria for each type of benefit.

Documentation 105

Documentation Immunization Mayo Clinic Insurance 105

STAT

JANUARY 19, 2024

Food and Drug Administration scolded Novartis for making false and misleading statements about a best-selling breast cancer treatment in a television ad in 2022. In a letter dated Thursday, the agency admonished the company for touting the benefits of its Kisqali medicine by referencing data that did not support the messages in the ad.

FDA 113

FDA 113

European Pharmaceutical Review

DECEMBER 1, 2023

The antibody-drug conjugate is the first to be approved for platinum-resistant ovarian cancer (PROC) and show meaningful survival benefit for this form of the disease. The new proposed addition to AbbVie’s portfolio The proposed acquisition will accelerate AbbVie’s entry into the commercial market for ovarian cancer.

FDA 108

FDA 108

Hospital Pharmacy Europe

SEPTEMBER 25, 2023

The kinase inhibitor ruxolitinib (brand name Jakavi) has been recommended in draft guidance by the UK’s National Institute for Health and Care Excellence (NICE) for the treatment of patients with the blood cancer polycythaemia vera (PV), its manufacturer Novartis has announced. PV is rare blood cancer affecting the bone marrow.

Hospitals 105

Hospitals 105

STAT

OCTOBER 5, 2023

The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground following a Food and Drug Administration advisory committee meeting Thursday. Regulatory advisers voted 10-2 that the data on the company’s drug Lumakras, a treatment for lung cancer, could not be properly assessed.

FDA 90

FDA 90

Pharmafile

DECEMBER 11, 2023

GSK has announced that the European Commission (EC) has granted marketing authorisation to Jemperli (dostarlimab) in combination with carboplatin-paclitaxel chemotherapy, for the treatment of adult patients with mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer.

Chemotherapy 64

Chemotherapy 64

The Checkup by Singlecare

MARCH 7, 2024

But if you don’t know why they’re present or if they don’t itch, the pink dots may be caused by an underlying condition or less obvious external factors. This condition occurs when the immune system has an allergic response to a substance, causing pink or red, itchy, irritated spots or patches on the skin. So can acne.

Immunization 97

Immunization 97

Outsourcing Pharma

SEPTEMBER 26, 2023

A rare and incurable blood cancer, associated with an overproduction of blood cells, that can lead to stroke or heart attack, will soon have access to a small molecule Novartis treatment for the condition.

76

76

European Pharmaceutical Review

DECEMBER 11, 2023

The European Commission (EC) has approved the first frontline immuno-oncology treatment in the EU for mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) primary advanced or recurrent endometrial cancer.

Chemotherapy 88

Chemotherapy 88

Hospital Pharmacy Europe

MAY 18, 2023

Pharmacists are among those who have been asked to respond to a consultation ahead of the Government’s major conditions strategy set to publish later this year. A call for evidence has been launched on how to prevent, diagnose, and manage six conditions that account for 60% of ill health and early deaths in England.

Hospitals 97

Hospitals 97

European Pharmaceutical Review

MAY 18, 2023

NICE’s conditional authorisation of Gilead’s chronic hepatitis D treatment The conditional marketing authorisation was granted based on the results of two Phase II studies, MYR202 and MYR203. SMC accepts treatment for chronic hepatitis delta virus HDV infection is relatively rare.

87

87

STAT

OCTOBER 27, 2022

As an oncologist and a leader at a national cancer organization, I’ve watched countless families celebrate the incredible news that their child has defeated a pediatric cancer. Treatments for pediatric cancers work well, but they come at a steep cost.

107

107

European Pharmaceutical Review

MARCH 29, 2023

Pembrolizumab (Keytruda) has been recommended in National Institute for Health and Care Excellence (NICE) final draft guidance for advanced cervical cancer. Clinical trial evidence shows that the treatment helps delay worsening of the disease , compared to standard care. It also suggests patients may live longer overall.

Chemotherapy 94

Chemotherapy 94

The Checkup by Singlecare

MARCH 13, 2024

Osteoporosis and bone density conditions are common in the U.S.—the the Centers for Disease Control and Prevention (CDC) estimates 1 in 5 women ages 50 and older have it—and these medications are crucial for treatment. What is Xgeva? It prevents serious bone problems in people with multiple myeloma or other bone tumors.

FDA 98

FDA Dosage Insurance 98

European Pharmaceutical Review

OCTOBER 17, 2023

In final guidance , the National Institute for Health and Care Excellence (NICE) has recommended glofitamab as a new treatment option for advanced lymphoma. NICE noted that clinical trial evidence suggests that some patients given glofitamab attained complete remission with no signs or symptoms of cancer. What is glofitamab?

FDA 105

FDA 105

STAT

APRIL 23, 2024

The FDA  approved a new immunotherapy  for advanced bladder cancer made by ImmunityBio. Escient is developing drugs to treat inflammatory skin conditions including chronic hives and liver-associated itching. Incyte  acquired  privately held Escient Pharmaceuticals for $750 million.

FDA 77

FDA 77

STAT

MAY 19, 2023

The Food and Drug Administration on Friday approved the first treatment for a devastating condition that causes the skin to be so fragile that even a touch can cause it to splinter, bringing another gene therapy onto the market. Scarring can cause fingers and toes to fuse together, and patients face high rates of skin cancer.

FDA 101

FDA 101

The Checkup by Singlecare

MARCH 22, 2024

Eczema is a type of dermatitis, a group of medical conditions that cause inflammation of the skin. People with skin conditions, allergies , or asthma (or a family history of one of these conditions) are at higher risk for eczema. The best treatment for eczema depends on the type and severity of symptoms.

Immunization 105

Immunization FDA Packaging Labelling 105

The Checkup by Singlecare

JANUARY 11, 2024

By far, the most common causes include irritation from soap and clothing, skin conditions like eczema , dry skin, and hormonal fluctuations. In rare cases, itchy nipples are caused by breast cancer. Treatments for itchy nipples vary by cause and may include topical lotions or steroids. What causes itchy nipples?

52

52

The Checkup by Singlecare

DECEMBER 21, 2023

But since its FDA approval for the treatment of Type 2 diabetes back in 1994, metformin has emerged as something of a “miracle drug” thanks to its effectiveness in treating other common health conditions, like infertility, obesity , and heart disease. Read on to learn about these proven effects and promising future uses of metformin.

Health and Personal Care Stores 105

Health and Personal Care Stores Labelling Dosage FDA 105

Pharma Mirror

NOVEMBER 30, 2023

By Alexei Voloshin, Global Head of Bioprocess Science, 3M Biopharmaceutical Purification Article Synopsis: Modern biotechnology has brought a revolution in improving the human condition around the world both in terms of quantity and quality.

52

52

STAT

OCTOBER 6, 2023

… The clearance of a first-of-its-kind cancer treatment made by Amgen is on shakier ground after a U.S. Food and Drug Administration advisory panel voted 10-2 that the data for the Lumakras lung cancer treatment could not be properly assessed , STAT reports. The Mirati received accelerated approval from U.S.

FDA 94

FDA 94

Pharmaceutical Technology

NOVEMBER 25, 2022

Japan’s Ministry of Health, Labour and Welfare (MHLW) has granted approval for Daiichi Sankyo ’s Enhertu (trastuzumab deruxtecan) to treat HER2-positive unresectable or recurrent breast cancer in adults. The treatment is indicated for usage in such patients following previous chemotherapy, comprising trastuzumab and a taxane.

Adverse Reactions 105

Adverse Reactions Chemotherapy Labelling 105

The Checkup by Singlecare

DECEMBER 26, 2023

However, there are a few conditions that can cause both symptoms: diverticulitis in the large intestine, gastrointestinal cancer, and frequent or heavy use of over-the-counter NSAIDs. Typically, lower back pain and black stool do not require treatment unless they do not stop on their own.

105

105

The Checkup by Singlecare

MARCH 21, 2024

Studies are also finding that Ozempic could potentially be used to address insulin resistance in conditions like polycystic ovary syndrome (PCOS) and fatty liver disease. Over time, this problem may contribute to metabolic syndrome, certain cancers, and even Alzheimer’s disease.

Dosage 98

Dosage Insurance Coverage Insurance Labelling 98

pharmaphorum

NOVEMBER 18, 2022

have announced a strategic research collaboration within the field of conditionally activated bispecific therapeutics for the treatment of cancer. Image sourced from: Cancer Research UK / Shutterstock. The post Regeneron, CytomX announce bispecific therapeutics for cancer collab appeared first on.

Immunization 104

Immunization 104

Hospital Pharmacy Europe

SEPTEMBER 11, 2023

Greater ethnic diversity in pioneering breast cancer clinical trials is the primary objective of a recent collaborative pilot project between Barts Health NHS Trust, The Christie NHS Foundation Trust, Roche Products Ltd and Macmillan Cancer Support.

Communication 105

Communication Hospitals 105

European Pharmaceutical Review

MAY 29, 2023

This genetic condition is defined by seizures starting during infancy. The committee recommended granting a marketing authorisation for Pylclari (piflufolastat (18F)), intended for the diagnosis of prostate cancer. The treatment is intended for the rare genetic disease fibrodysplasia ossificans progressive.

92

92

European Pharmaceutical Review

OCTOBER 9, 2023

The medicine is approved in the US for advanced KRAS G12C -mutated non-small cell lung cancer (NSCLC) in patients who have received at least one prior systemic treatment. The treatment has shown encouraging early efficacy data in NSCLC, bile duct cancer (cholangiocarcinoma) and melanoma.

94

94

Pharmaceutical Technology

OCTOBER 10, 2023

The Scottish Medicines Consortium accepted 12 new treatments for conditions ranging from cancer to obesity.

52

52

STAT

DECEMBER 21, 2023

Several of the largest medical marijuana companies, like Trulieve, Curaleaf, and Verano, are advertising their products as treatments not just for muscle aches, but for major medical conditions like cancer and depression, without evidence to back up those claims.

Pharmaceutical Companies 119

Pharmaceutical Companies Pharmaceutical Companies FDA 119

STAT

OCTOBER 21, 2022

The clinical trial enterprise, however, has yet to appreciate caregivers — and fully engage them — as critical partners in recruiting and supporting people who are older, disabled, or have Alzheimer’s disease, cancer, or other chronic medical conditions for research studies. Read the rest…

106

106

STAT

OCTOBER 4, 2023

And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth. At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021.

Documentation 117

Documentation FDA 117

European Pharmaceutical Review

AUGUST 23, 2023

Eli Lilly and Company ’s highly selective and potent RET kinase inhibitor for advanced medullary thyroid cancer (MTC) has demonstrated superior progression-free survival (PFS) compared to approved multikinase inhibitors. The post Eli Lilly therapeutic shows potential in thyroid cancer appeared first on European Pharmaceutical Review.

94

94

European Pharmaceutical Review

OCTOBER 4, 2023

Radioligand therapy works by directly targeting cancer by linking a radioisotope to a targeting molecule that delivers radiation directly to cancer cells, Eli Lilly stated. The treatment is currently being studied in a Phase III trial. What radioligand therapies will be developed under the acquisition agreement?

100

100